• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

超声检查联合超声造影可预测淋巴细胞为主型乳腺癌。

Ultrasonography Combined With Contrast-enhanced Ultrasonography Can Predict Lymphocyte-predominant Breast Cancer.

作者信息

Fukui Kayo, Masumoto Norio, Yokoyama Erika, Kanou Akiko, Yokozaki Michiya, Sasada Shinsuke, Emi Akiko, Kadoya Takayuki, Arihiro Koji, Okada Morihito

机构信息

Division of Laboratory Medicine, Hiroshima University Hospital, Hiroshima, Japan.

Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine,Hiroshima University, Hiroshima, Japan.

出版信息

Cancer Diagn Progn. 2021 Jul 3;1(4):309-316. doi: 10.21873/cdp.10041. eCollection 2021 Sep-Oct.

DOI:10.21873/cdp.10041
PMID:35403146
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8988962/
Abstract

BACKGROUND

We investigated whether contrast-enhanced ultrasonography (CEUS) scores can predict lymphocyte-predominant breast cancer (LPBC).

PATIENTS AND METHODS

We evaluated 75 patients who underwent US and CEUS. LPBC was defined as tissues with ≥50% stromal tumour-infiltrating lymphocytes (TILs) preoperatively. Characteristic US images predicting LPBC were evaluated using TIL-US scores via three ultrasonic tissue characteristics: Shape, internal echo level, and posterior echoes. TIL-CEUS was evaluated based on TIL-US plus CEUS.

RESULTS

TIL-US and TIL-CEUS cut-offs for predicting LPBC were 4 and 6 (area under the curve=0.93 and 0.96, respectively) points based on receiver operating characteristics curves. Sensitivity, specificity, and accuracy values (95% confidence intervaI) were 0.94 (0.77-0.99), 0.75 (0.70-0.77), and 0.80 (0.72-0.82); and 0.94 (0.78-0.99), 0.86 (0.81-0.87), and 0.88 (0.80-0.90) for TIL-US and TIL-CEUS, respectively. TIL-CEUS score was a significant single predictor for LPBC in multivariate logistic regression (p=0.001).

CONCLUSION

TIL-CEUS can be used for preoperative LPBC prediction and detection.

摘要

背景

我们研究了超声造影(CEUS)评分是否能够预测淋巴细胞为主型乳腺癌(LPBC)。

患者与方法

我们评估了75例接受超声检查和CEUS检查的患者。LPBC术前定义为基质肿瘤浸润淋巴细胞(TILs)≥50%的组织。通过形状、内部回声水平和后方回声这三个超声组织特征,使用TIL-US评分来评估预测LPBC的特征性超声图像。TIL-CEUS基于TIL-US加CEUS进行评估。

结果

基于受试者工作特征曲线,预测LPBC的TIL-US和TIL-CEUS截断值分别为4分和6分(曲线下面积分别为0.93和0.96)。TIL-US和TIL-CEUS的敏感性、特异性和准确性值(95%置信区间)分别为0.94(0.77 - 0.99)、0.75(0.70 - 0.77)、0.80(0.72 - 0.82);以及0.94(0.78 - 0.99)、0.86(0.81 - 0.87)、0.88(0.80 - 0.90)。在多因素逻辑回归中,TIL-CEUS评分是LPBC的显著单一预测指标(p = 0.001)。

结论

TIL-CEUS可用于LPBC的术前预测和检测。

相似文献

1
Ultrasonography Combined With Contrast-enhanced Ultrasonography Can Predict Lymphocyte-predominant Breast Cancer.超声检查联合超声造影可预测淋巴细胞为主型乳腺癌。
Cancer Diagn Progn. 2021 Jul 3;1(4):309-316. doi: 10.21873/cdp.10041. eCollection 2021 Sep-Oct.
2
The tumor-infiltrating lymphocyte ultrasonography score can provide a diagnostic prediction of lymphocyte-predominant breast cancer preoperatively.肿瘤浸润淋巴细胞超声评分可术前对淋巴细胞为主型乳腺癌提供诊断预测。
J Med Ultrason (2001). 2022 Oct;49(4):709-717. doi: 10.1007/s10396-022-01240-4. Epub 2022 Aug 24.
3
Novel tumor-infiltrating lymphocytes ultrasonography score based on ultrasonic tissue findings predicts tumor-infiltrating lymphocytes in breast cancer.基于超声组织特征的新型肿瘤浸润淋巴细胞超声评分预测乳腺癌中的肿瘤浸润淋巴细胞。
Breast Cancer. 2019 Sep;26(5):573-580. doi: 10.1007/s12282-019-00958-3. Epub 2019 Mar 13.
4
Evaluating Tumor-Infiltrating Lymphocytes in Breast Cancer: The Role of Conventional Ultrasound and Contrast-Enhanced Ultrasound.评估乳腺癌中的肿瘤浸润淋巴细胞:传统超声和超声造影的作用
J Ultrasound Med. 2023 Feb;42(3):623-634. doi: 10.1002/jum.16058. Epub 2022 Jul 21.
5
Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy.新辅助化疗治疗三阴性乳腺癌中肿瘤浸润淋巴细胞的预测和预后影响
Ecancermedicalscience. 2017 Aug 15;11:759. doi: 10.3332/ecancer.2017.759. eCollection 2017.
6
The TILs-US score on ultrasonography can predict the pathological response to neoadjuvant chemotherapy for human epidermal growth factor receptor 2-positive and triple-negative breast cancer.超声检查的 TILs-US 评分可预测人表皮生长因子受体 2 阳性和三阴性乳腺癌新辅助化疗的病理反应。
Surg Oncol. 2022 May;41:101725. doi: 10.1016/j.suronc.2022.101725. Epub 2022 Feb 15.
7
Diagnostic performance of TILs-US score and LPBC in biopsy specimens for predicting pathological complete response in patients with breast cancer.TILs-US 评分和 LPBC 在乳腺癌活检标本中预测病理完全缓解的诊断性能。
Int J Clin Oncol. 2024 Dec;29(12):1860-1869. doi: 10.1007/s10147-024-02634-9. Epub 2024 Oct 3.
8
Associations between absolute neutrophil count and lymphocyte-predominant breast cancer.中性粒细胞计数与淋巴细胞为主型乳腺癌的相关性。
Breast. 2020 Apr;50:141-148. doi: 10.1016/j.breast.2019.09.013. Epub 2019 Oct 3.
9
Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer.肿瘤浸润淋巴细胞:新辅助治疗 HER2 阳性乳腺癌的预测和预后生物标志物。
Clin Cancer Res. 2016 Dec 1;22(23):5747-5754. doi: 10.1158/1078-0432.CCR-15-2338. Epub 2016 May 17.
10
Changes of Tumor Infiltrating Lymphocytes after Core Needle Biopsy and the Prognostic Implications in Early Stage Breast Cancer: A Retrospective Study.早期乳腺癌核心针活检后肿瘤浸润淋巴细胞的变化及其预后意义:一项回顾性研究。
Cancer Res Treat. 2019 Oct;51(4):1336-1346. doi: 10.4143/crt.2018.504. Epub 2019 Feb 12.

引用本文的文献

1
Prediction value study of breast cancer tumor infiltrating lymphocyte levels based on ultrasound imaging radiomics.基于超声成像放射组学的乳腺癌肿瘤浸润淋巴细胞水平预测价值研究
Front Oncol. 2024 Jun 6;14:1411261. doi: 10.3389/fonc.2024.1411261. eCollection 2024.
2
Tumor infiltrating lymphocytes and radiological picture of the tumor.肿瘤浸润淋巴细胞和肿瘤的影像学表现。
Med Oncol. 2023 May 13;40(6):176. doi: 10.1007/s12032-023-02036-3.
3
Multimodality Imaging Assessment of Desmoid Tumors: The Great Mime in the Era of Multidisciplinary Teams.韧带样瘤的多模态成像评估:多学科团队时代的“伟大模仿者”
J Pers Med. 2022 Jul 16;12(7):1153. doi: 10.3390/jpm12071153.

本文引用的文献

1
Novel tumor-infiltrating lymphocytes ultrasonography score based on ultrasonic tissue findings predicts tumor-infiltrating lymphocytes in breast cancer.基于超声组织特征的新型肿瘤浸润淋巴细胞超声评分预测乳腺癌中的肿瘤浸润淋巴细胞。
Breast Cancer. 2019 Sep;26(5):573-580. doi: 10.1007/s12282-019-00958-3. Epub 2019 Mar 13.
2
Quantitative Multiparametric Breast Ultrasound: Application of Contrast-Enhanced Ultrasound and Elastography Leads to an Improved Differentiation of Benign and Malignant Lesions.定量多参数乳腺超声:对比增强超声和弹性成像的应用可改善良恶性病变的鉴别诊断。
Invest Radiol. 2019 May;54(5):257-264. doi: 10.1097/RLI.0000000000000543.
3
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.浸润淋巴细胞与不同亚型乳腺癌患者预后的关系:新辅助化疗治疗 3771 例患者的汇总分析
Lancet Oncol. 2018 Jan;19(1):40-50. doi: 10.1016/S1470-2045(17)30904-X. Epub 2017 Dec 7.
4
Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group.乳腺癌肿瘤浸润淋巴细胞的标准化评估:国际免疫肿瘤生物标志物工作组环研究的结果。
Mod Pathol. 2016 Oct;29(10):1155-64. doi: 10.1038/modpathol.2016.109. Epub 2016 Jul 1.
5
Evaluation of Malignancy Grade of Breast Cancer Using Perflubutane-Enhanced Ultrasonography.使用全氟丁烷增强超声评估乳腺癌的恶性程度
Ultrasound Med Biol. 2016 May;42(5):1049-57. doi: 10.1016/j.ultrasmedbio.2015.12.023. Epub 2016 Feb 16.
6
Ability of contrast-enhanced ultrasonography to determine clinical responses of breast cancer to neoadjuvant chemotherapy.超声造影评估乳腺癌新辅助化疗临床疗效的能力
Jpn J Clin Oncol. 2016 Apr;46(4):303-9. doi: 10.1093/jjco/hyv215. Epub 2016 Feb 3.
7
Sensitivity and specificity of mammography and adjunctive ultrasonography to screen for breast cancer in the Japan Strategic Anti-cancer Randomized Trial (J-START): a randomised controlled trial.钼靶 X 线摄影和附加超声检查筛查乳腺癌的敏感性和特异性:日本策略性抗癌随机试验(J-START):一项随机对照试验。
Lancet. 2016 Jan 23;387(10016):341-348. doi: 10.1016/S0140-6736(15)00774-6. Epub 2015 Nov 5.
8
Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.早期 HER2 阳性乳腺癌患者 N9831 辅助试验中基质肿瘤浸润淋巴细胞与无复发生存的相关性。
JAMA Oncol. 2016 Jan;2(1):56-64. doi: 10.1001/jamaoncol.2015.3239.
9
Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.人表皮生长因子受体 2 阳性和三阴性原发性乳腺癌中肿瘤浸润淋巴细胞与新辅助化疗联合或不联合卡铂的疗效。
J Clin Oncol. 2015 Mar 20;33(9):983-91. doi: 10.1200/JCO.2014.58.1967. Epub 2014 Dec 22.
10
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.2014年国际肿瘤浸润淋巴细胞(TILs)工作组对乳腺癌中肿瘤浸润淋巴细胞的评估建议
Ann Oncol. 2015 Feb;26(2):259-71. doi: 10.1093/annonc/mdu450. Epub 2014 Sep 11.